

Introduction



increased expenditure for clinical research budgets.

The financial pressure regarding the research budgets of pharmaceutical- and biotechnology companies entails a need for these companies to effectively optimise their limited budgets. In the future, strategies will be needed to assess tolerability, pharmacokinetics and efficacy in humans earlier, faster and with maximum cost effectiveness in order to filter out the compounds with the highest marketability. Fast recruitment and availability of patients for clinical trials as scheduled is of extreme importance. It is well known to all insiders of the clinical research business, that in Western European countries and USA qualified trial centres – in general university centres or CROs having their own clinic – are no longer able to conduct the amount of existing research projects within the desired timeframes. One of the central problems is patient recruitment within a desired time frame.

INNOPHAR Innovative Pharma Research Eastern Europe GmbH (IPR-EE) and its subcontractors Pharm PlanNet – Ukraine Clinic Ltd (PPN-UA) and **INNOPHAR** Innovative Pharma Research Moldova (IPR-MD) can offer you cost effective and time saving solutions to investigate safety, pharmacokinetics and first efficacy in man in your new compound within six months.

PPN-UA, is the first private clinic in Ukraine, specialised exclusively in the conduction of clinical research and combines professional CRO skills with academic expertise in collaboration with members of the Bukovinian State Medical University.

IPR-MD is located at the National Institute of Cardiology and is operated in collaboration with members of the Medical University of Chisinau.

In both countries IPR-EE and the local sites have good connections to health authorities

Dr. Karl M. Eckl
Executive Director/Medical Director

Location of sites of IPR-EE

Currently IPR-EE operates two clinical sites, one in Boyane close to Chernivtsi, Ukraine and one in Chisinau, Moldova.



Ukraine - Boyan:



The site at Boyan is currently equipped with up to 36 clinic beds.

Moldova - Chisinau:

The site in Chisinau is equipped with 24 clinic beds.

The site at Boyan can be reached by using the international airports in Lvov or Kiev. There are daily flights from Kiev to Chernivtsi and back. Chisinau has an international airport with flight connections to European cities.

Ukrainian health authorities are currently adapting their legal framework for conduction of clinical trials to international standards.

The IPR-EE clinical teams



All trials are conducted by the same well trained clinical team consisting of physicians experienced in the treatment of emergency

cases. The clinical teams of the IPR-EE sites are continuously trained. The team has great experience in practical application of GCP and other international guidelines. Expertise is documented in training logs and CVs.



Medical responsibility



is covered by academic experts like Prof. Semen Biletski, a well known internal specialist and cardiologist in Ukraine and head of the department of general medicine at the Bukovinian State Medical University.

Patients are available from all major therapeutic areas. The IPR-EE clinical sites have established several recruitment centres in policlinics. After selection of suitable patients according to the protocol they are hospitalised in the IPR-EE clinical sites. Experts in the different therapeutic areas can be recruited as investigators/sub-investigators or if special expertise or investigations are needed from the medical universities at Chernivtsi, Ukraine and Chisinau, Moldova.

The standards of the IPR-EE clinical sites

All main procedures within IPR-EE clinical sites are standardised and documented in Standard Operating Procedures. The quality of data is guaranteed by an own quality control group.



The IPR-EE clinical sites are headed by Dr. Karl M. Eckl who has 20 years of experience in drug development on an international level. He was investigator or sub-investigator for more than 300 clinical trials in the past.



Laboratory staff members are trained in appropriate sample handling- and storage procedures. Sample handling is documented for each sample individually.

AAI Deutschland GmbH & CoKG a GLP certified Analytical laboratory guarantees acceptance of analytical data by European Health Authorities. IPR-EE has also a contract of collaboration with AAI Deutschland GmbH & CoKG on data management, pharmacokinetics, statistics and report writing.



How to contact IPR-EE?

You can contact IPR-EE via the following addresses:

INNOPHAR GmbH
Innovative Pharma Research Eastern Europe



Dr. Franz Janik
Executive Director
Director Business Development
Johann-Strauß-Str. 30
D-89231 Neu-Ulm
Germany
Tel.: +49-(0)731-3885085
Fax: +49-(0)731-38900944
e-mail: franz.janik@innophar.de

INNOPHAR GmbH
Innovative Pharma Research Eastern Europe

Dr. Karl M. Eckl
Executive and Medical Director
Dorfstrasse 9
D-94344 Wiesenfelden
Germany
Tel.: + 49-(0)9966-90215-0
Fax: + 49-(0)9966-90215-15
e-mail: karl.eckl@innophar.de

INNOPHAR GmbH
Innovative Pharma Research
Eastern Europe

Your Partner for Proof of Concept Trials